A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years

Study identifier:D7260C00008

ClinicalTrials.gov identifier:NCT07455825

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A Phase I, Randomized, Single-dose, 3-Period, Open-Label Study to Assess the Pharmacokinetic Formulation Bridging, Safety, and Food Effect of Different Oral Formulations of AZD5004 in Healthy Participants

Medical condition

Healthy Participants

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD5004

Sex

All

Estimated Enrollment

64

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 05 Mar 2026
Estimated Primary Completion Date: 01 Jun 2026
Estimated Study Completion Date: 01 Jun 2026

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Crossover Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Mar 2026 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria